Similarly, selpercatinib has shown an ORR of 64% in RET fusion-positive NSCLC patients, who had previously been treated with RET therapy and an ORR of 85% in patients, who had not received previous RET therapy (Drilon et al., 2019b, 2020; Wirth et al., 2019). Here, RET is linked to non-small cell lung carcinoma.